Drug Research
STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures
STORM Therapeutics, the leading drug discovery company focused on small molecule therapies modulating RNA modifying enzymes, announced that it has raised an additional GBP4 million of funding from Taiho Ventures, LLC the strategic corporate venture capital arm of Taiho...
Drug Research
Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment...
Drug Research
NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners. ...
Drug Research
Idorsia forms research collaboration with Roche in the field of cancer immunotherapy
Idorsia Ltd announced that it has entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds for a promising new approach in the field of cancer immunotherapy. ...
Drug Research
NorthSea Therapeutics Secures €25 Million Funding for Clinical Development of Promising NASH Drug
NorthSea Therapeutics B.V. , a newly established Dutch biotech company, announced the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment of...
Drug Research
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint® BluePrint® Breast Cancer Kit Co-Validation Study
Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and Institute Curie in Paris, France, a leading player in the fight against cancer. Announce a co-validation partnership for Agendia’s new in vitro diagnostic (IVD)...
Drug Research
Torque Launches Platform to Develop New Class of Deep Primed Immune Cell Therapies
Torque, an immuno-oncology company developing Deep Primed cell therapies that direct and evoke immune responses in the tumor microenvironment, announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















